Previous 10 | Next 10 |
2023-10-15 08:05:05 ET Summary Castle Biosciences, Inc. has seen a significant decline in its stock value since early 2021, despite impressive revenue growth and a solid balance sheet. The company offers diagnostic and prognostic testing services for dermatological cancers, and an...
Study shows the DecisionDx-Melanoma test identifies more patients who can safely forego SLNB than using current guidelines alone or a clinicopathologic-only nomogram Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, tod...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will share new data demonstrating the ability of its DecisionDx ® -SCC test to identify node-negative cutaneous squamous cell carcinoma (SCC) patients at a higher risk of...
Data shared via a poster presentation at the recent American Foregut Society (AFS) Annual Meeting Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data demonstrating the significant clinical utility...
Studies have shown that using Castle’s DecisionDx ® -Melanoma test to help guide the care of patients with melanoma, the deadliest form of skin cancer, improves health outcomes 1-5 Castle’s management team will also ring the New York Stock Exchange closing bell ...
National award recognizes Castle’s strong culture and employee engagement Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has earned a Top Workplaces National Industry Award, ranking thi...
The study , published in Gastroenterology, shows TissueCypher can increase the detection of Barrett’s esophagus (BE) patients with an initial diagnosis of low-grade dysplasia (LGD) who will progress to high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC) Castle B...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that the Company has received its Clinical Laboratory Permit from the New York State Department of Health for its laboratory in Pittsburgh. “Castle is c...
IDgenetix is a clinically validated pharmacogenomic (PGx) test that incorporates the results of drug-gene interactions with drug-drug interactions and lifestyle factors, such as smoking and use of over-the-counter medicines and dietary supplements, to provide medication recommendations for patien...
The TissueCypher Barrett’s Esophagus test can identify patients at a higher or lower risk of developing esophageal cancer than indicated by pathologic diagnoses and clinical risk factors to guide escalated or de-escalated patient management Data to be highlighted at the 19t...
News, Short Squeeze, Breakout and More Instantly...
Castle Biosciences Inc. Company Name:
CSTL Stock Symbol:
NYSE Market:
Castle Biosciences Inc. Website:
Campaign will focus on empowering patients impacted by melanoma Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, has joined forces with television personality, wellness coach and founder of ALL IN by Teddi, host of the...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the second quarter and six months ended June 30, 2024, after the close of market on Monday, Aug. 5, 2024. Compan...
Castle earns recognition as an Arizona Top Workplace, a national Healthcare Industry Top Workplace and receives five Top Workplaces Culture Excellence Awards Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today annou...